Who is Claire Mazumdar ? Kiran Mazumdar Shaw’s Successor at Biocon

Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm incubated by Biocon.

She holds a Bachelor of Science in Biological Engineering from MIT, earned her MBA from Stanford Graduate School of Business and a PhD in Cancer Biology from Stanford School of Medicine. Her research in tumor immunology and cancer epigenetics has been published in Nature, Cell Stem Cell and Cancer Cell.

She is the founding CEO of Bicara Therapeutics, Claire Mazumdar, led business development and corporate strategy at Rheos Medicines, where she supported a major partnership with Roche. As a Senior Associate at Third Rock Ventures, she focused on company formation and supported business development for TRV portfolio companies. She is also a Member of the Board of Directors for Noora Health, a global non-profit which works to improve patient outcomes and strengthen health systems by equipping family caregivers with the skills they need to care for their loved ones.

Biocon founder and chairperson Kiran Mazumdar-Shaw has formally outlined a succession plan for her biotechnology company, naming her niece Claire Mazumdar as her chosen successor. Mazumdar-Shaw, 73, who built Biocon into a leading biopharmaceutical enterprise over nearly four decades, said she is focused on ensuring the company remains in capable hands. As the sole owner with no children, she views Claire as a natural successor, citing her proven leadership and ability to run a global biotech business.